文献速递胸部肿瘤放疗

不可手术非小细胞肺癌同步放化疗后放疗剂量与局部进展及总生存的关系

Radiation Dose, Local Disease Progression, and Overall Survival in Patients With Inoperable Non-Small Cell Lung Cancer After Concurrent Chemoradiation Therapy.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2017-10-12

该研究纳入491例IIIA-IIIB期不可手术非小细胞肺癌患者,接受60-74Gy同步放化疗,按剂量分组分析局部进展(LP)和总生存(OS)的预测因素。结果显示67-70Gy组无局部进展生存(LPFS)优于60-63Gy和64-66Gy组,LPFS是OS的唯一独立预测因素,≥3级放射性肺炎发生率各组无差异。

要点

  • 67-70Gy组LPFS优于60-63Gy和64-66Gy组。
  • 鳞癌、大肿瘤体积和诱导化疗预测更差LPFS。
  • LPFS是OS的唯一独立预测因素。

核心结论

  • 67-70Gy剂量与同步放化疗后改善的无局部进展生存相关。
  • 局部进展与总生存降低相关,提示需要更有效的局部控制策略。

研究设计与样本

  • 回顾性分析491例新诊断IIIA-IIIB期不可手术非小细胞肺癌患者,2005年1月至2013年12月接受60-74Gy同步化疗,按剂量分为60-63Gy、64-66Gy、67-70Gy、71-74Gy四组,采用Cox回归模型分析LP和OS的预测因素。

主要发现

  • 全部患者1、2、3、4、5年局部进展率分别为16.2%、26.2%、31.0%、32.9%、32.9%,对应OS率分别为85.3%、61.2%、44.5%、37.0%、31.6%,中位OS为21个月(范围2.9-99.9个月)。
  • 多因素分析中,67-70Gy组LPFS优于60-63Gy组(HR 1.83,95%CI 1.062-3.150,P=.030)和64-66Gy组(HR 2.14,95%CI 1.159-3.969,P=.015)。
  • 非鳞癌组织学(HR 0.23,95%CI 0.114-0.478,P=.000)、大体肿瘤体积(HR 1.00,95%CI 1.000-1.003,P=.018)和诱导化疗(HR 1.86,95%CI 1.239-2.778,P=.003)是LPFS的独立预测因素。
  • LPFS是OS的唯一独立预测因素(HR 2.71,95%CI 1.331-5.512,P=.006)。
  • ≥3级放射性肺炎发生率在各剂量组间无差异(P=.307)。

临床怎么用

  • 对于不可手术IIIA-IIIB期非小细胞肺癌接受同步放化疗者,可考虑给予67-70Gy剂量以改善局部控制。
  • 鳞癌、大肿瘤体积或接受诱导化疗的患者局部进展风险更高,需加强局部控制策略。

局限性

  • 回顾性研究设计可能引入选择偏倚。
  • 局部进展定义为高剂量体积(计划靶体积加1cm边缘)内出现,可能受定义影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To identify predictors of local control and overall survival (OS) for patients with inoperable non-small cell lung cancer treated with concurrent chemoradiation therapy. METHODS AND MATERIALS: We identified 491 patients with newly diagnosed stage IIIA-IIIB non-small cell lung cancer who had received 60 to 74 Gy (with concurrent chemotherapy) from January 2005 through December 2013 and grouped them by radiation dose received: 60 to 63 Gy, 64 to 66 Gy, 67 to 70 Gy, or 71 to 74 Gy. Local progression (LP) was that appearing within the high-dose volume (planning target volume plus 1-cm margin). Times to events were calculated from the completion of radiation therapy. Potential predictors of LP and OS were analyzed with a Cox regression model. RESULTS: Rates of LP for all patients were 16.2% at 1 year, 26.2% at 2 years, 31.0% at 3 years, 32.9% at 4 years, and 32.9% at 5 years; corresponding OS rates were 85.3%, 61.2%, 44.5%, 37.0%, and 31.6%. Median OS time was 21 months (range, 2.9-99.9 months). In multivariate analysis, receipt of 67 to 70 Gy was associated with improved LP-free survival (LPFS) relative to 60 to 63 Gy (hazard ratio [HR] 1.83, 95% confidence interval [CI] 1.062-3.150, P=.030) or 64 to 66 Gy (HR 2.14, 95% CI 1.159-3.969, P=.015). Non-squamous histology (HR 0.23, 95% CI 0.114-0.478, P=.000), gross tumor volume (HR 1.00, 95% CI 1.000-1.003, P=.018) and induction chemotherapy (HR 1.86, 95% CI 1.239-2.778, P=.003) were independent predictors of LPFS. Local progression-free survival was the only independent predictor of OS (HR 2.71, 95% CI 1.331-5.512, P=.006). Incidence of grade ≥3 radiation pneumonitis was no different among dose groups (P=.307). CONCLUSIONS: Squamous histology, large tumor volumes, and receipt of induction chemotherapy all predicted worse LPFS. Doses of 67 to 70 Gy were associated with improved LP-free survival after chemoradiotherapy. The link between LP and reduced OS suggests that more effective local control strategies are warranted.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Zhou R, Xu T, Nguyen QN, et al. Radiation Dose, Local Disease Progression, and Overall Survival in Patients With Inoperable Non-Small Cell Lung Cancer After Concurrent Chemoradiation Therapy. Int J Radiat Oncol Biol Phys. 2017. PMID: 29174428. doi:10.1016/j.ijrobp.2017.10.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。